All News
Filter News
Found 509 articles
-
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
6/1/2023
IO Biotech announced that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.
-
IO Biotech to Present at the 2023 Jefferies Healthcare Conference
5/30/2023
IO Biotech announced that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference to be held June 7-9 in New York City.
-
The New York–based biotech will present data from a Phase I trial of 98 patients showing that fianlimab combined with Libtayo led to an overall response rate of 61% in advanced melanoma.
-
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
5/16/2023
Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088.
-
IO Biotech Announces 2023 First-Quarter Results
5/11/2023
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced financial results for the first quarter ended March 31, 2023.
-
PharmAbcine to participate in BIO International Convention 2023
5/8/2023
PharmAbcine Inc. announced today that the company will participate in the upcoming BIO International Convention 2023.
-
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
5/8/2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate progress.
-
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
4/27/2023
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2023 Company’s outlook.
-
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
4/20/2023
OSE Immunotherapeutics SA presented two additional posters reporting the latest research updates on CLEC-1, from its Myeloid platform, at the 2023 American Association for Cancer Research Annual Meeting held in Orlando on April 14-19.
-
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
4/18/2023
OSE Immunotherapeutics SA announces three presentations at the American Association for Cancer Research Annual Meeting in Orlando, April 14-19, 2023.
-
BostonGene Highlights Comprehensive Approach to Precision Medicine at hubXchange’s East Coast Genomics in Precision Oncology 2023
4/3/2023
BostonGene announced that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts.
-
PharmaBlock Opens New R&D Facility in Pennsylvania
3/27/2023
Expanding Capacity to Deliver GMP Projects
-
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
3/15/2023
Aravive, Inc. today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.
-
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
3/14/2023
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced financial results for the fourth quarter and year-ended December 31, 2022.
-
Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards
3/7/2023
Oxford BioTherapeutics Ltd. announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.
-
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
2/27/2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.
-
binx health to Present at the Upcoming BioCapital Europe 2023 Conference
2/23/2023
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announced today that Jeff Luber, Chief Executive Officer, will present at the BioCapital Europe 2023, a life sciences investment conference taking place on March 9, 2023, in Amsterdam, the Netherlands.
-
IO Biotech to Participate in March 2023 Investor Conferences
2/22/2023
IO Biotech today announced participation in two upcoming investor conferences.
-
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
2/15/2023
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (ICI).
-
BostonGene Showcases Comprehensive Approach to Precision Medicine at Immuno-Oncology 360°
2/7/2023
BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York.